I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Roisin Maritxell Connolly, M.B.B.Ch., M.D.
Associate Professor of Oncology
Languages: English, French, German, Irish
Expertise: Breast Cancer, Clinical Trials, Medical Oncology
Research Interests: Breast Cancer; Epigenetics; Immunotherapy; Clinical Trials
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
The Johns Hopkins Hospital (Main Entrance)
APPOINTMENT PHONE: 410-955-8964
1800 Orleans St. Sheikh Zayed Tower Baltimore, MD 21287
Dr. Roisin Connolly is an assistant professor of oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Connolly is a member of the Breast and Ovarian Cancer Program and co-directs the Phase I Clinical Trials Program for the Kimmel Cancer Center.
Dr. Connolly completed her internal medicine training in Ireland and Australia. She commenced her medical oncology fellowship training in Ireland on the Specialist Registrar in Medical Oncology Training Scheme. She subsequently undertook further training in the Medical Oncology Fellowship Program at the Kimmel Cancer Center.
Dr. Connolly joined the faculty at Johns Hopkins in 2011 where her principal research activities consist of designing and conducting clinical trials that test investigational new drugs in the treatment of breast cancer. She has specific expertise in the use of epigenetic modifiers and in developing biomarkers of response to breast cancer therapies. She is principal investigator for a number of multicenter trials in collaboration with the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute, the Translational Breast Cancer Research Consortium (TBCRC), and the Eastern Co-operative Oncology Group (ECOG)-ACRIN. Dr. Connolly is study chair for a phase III ECOG-ACRIN study (E2112) investigating the HDAC inhibitor entinostat in combination with hormonal therapy in women with metastatic breast cancer. As a clinical investigator with a focus on translational drug development, her goal is to improve outcomes for patients with breast cancer.
- Associate Professor of Oncology
Centers & Institutes
- MBBCh, University of Dublin Trinity College (2001)
- MD, University of Dublin Trinity College (2016)
- Royal Perth Hospital (2003)
- Royal College of Physicians Ireland / Internal Medicine (2005)
- Royal College of Physicians Ireland / Medical Oncology (2008)
- Johns Hopkins University School of Medicine / Oncology (2011)
- Pending/Scheduled / Oncology
Research & Publications
Selected PublicationsView all on Pubmed
Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Fetting JH, Emens LA, Stearns V, Davidson NE, Baker SD, Wolff AC. Docetaxel Metabolism is not Altered by Imatinib: Findings from an Early Phase Study in Metastatic Breast Cancer. Breast Cancer Research and Treatment 2011, May; 127 (1): 153-62. (PMID 21350820)
Rudek MA*, Connolly RM*, Hoskins JM, Garrett-Mayer E, Jeter SC, Armstrong DK, Fetting JH, Stearns V, Wright LA, Zhao M, Watkins SP, McLeod HL, Davidson NE, Wolff AC. Fixed Dose Capecitabine is Feasible: Results from a Pharmacokinetic and Pharmacogenetic Study in Metastatic Breast Cancer. Breast Cancer Research and Treatment 2013. May;139(1):135-43 (PMID 23588952) *Co-first authors
Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, Topper MJ, Luo J, Connolly RM, Azad NS, Stearns V, Pardoll DM, Davidson N, Jones PA, Slamon DJ, Baylin SB, Zahnow CA, Ahuja N. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014 Feb 15;5(3):587-98.(PMID 24583822)
Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, Mhlanga J, O JH, Carpenter J, Storniolo AM, Watkins S, Fetting J, Miller R, Sideras K, Jeter SC, Walsh B, Powers P, Zorzi J, Boughey J, Davidson NE, Carey LA, Wolff AC, Khouri N, Gabrielson E, Wahl RL, Stearns V. TBCRC 008: Randomized Phase II Study Evaluating Response and Treatment-Selection Biomarkers to Preoperative Carboplatin and Nanoparticle Albumin-bound Paclitaxel with or without Vorinostat in HER2-negative Primary Operable Breast Cancer. Journal of Nuclear Medicine 2015; 56(1):31-7 (PMID: 25476537)
Freedman RA, Gelman RS, Wefel JS, Krop IE, Melisko ME, Lowe A, Agar NYR, Blackwell KL, Connolly RM, Niravath PA, Van Poznak CH, Puhalla SL, Ryabin N, Lawler E, Ibrahim N, Liu M, Wolff AC, Winer EP, Lin N. TBCRC 022: Phase II Trial of Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases. JCO 2016 Feb 1 (Epub ahead of print)